Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769820 | 0.81 | ALDH1A1 (0.36) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15032497 | 0.80 | — | — | |
| SCHEMBL12206794 | 0.80 | ADORA2A (0.36) | SMN1; SMN2CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL15468852 | 0.80 | ADORA2A (0.33) | — | |
| SCHEMBL14769830 | 0.79 | SMN1; SMN2 (0.33) | KDM4ESMN1; SMN2 | |
| SCHEMBL17282462 | 0.77 | KDM4E (0.33) | KDM4ESMN1; SMN2EGFRPTK2 | |
| SCHEMBL21392460 | 0.72 | LMNA (0.33) | — | |
| SCHEMBL26772821 | 0.72 | NQO1 (0.33) | ALDH1A1 | |
| SCHEMBL2515269 | 0.71 | KDM4E (0.34) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL26354716 | 0.71 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-9862743-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20160331770-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2016-11-17 | — | — | US | disclosed |
| US-9441007-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9422322-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9346848-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9315535-B2 | Nucleoside and nucleotide having nitrogen-containing heterocycle structure | SHIONOGI & CO., LTD. (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150368287-A1 | NUCLEOSIDE AND NUCLEOTIDE HAVING NITROGEN-CONTAINING HETEROCYCLE STRUCTURE | SHIONOGI & CO., LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150337002-A1 | NUCLEOSIDE AND NUCLEOTIDE HAVING SULFONAMIDE STRUCTURE | SHIONOGI & CO., LTD. (JP) | 2015-11-26 | — | — | US | disclosed |
| US-8980865-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2015-02-19 | — | — | US | disclosed |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV | 2015-01-01 | — | — | US | disclosed |
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2014-10-09 | — | — | US | disclosed |
| US-8772474-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130252920-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG | VERTEX PHARMACEUTICALS INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303108-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | ALDH1A1 2755/4885KDM4E 4023/4885GLA 3411/4885 |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | ALDH1A1 3576/4885KDM4E 2699/4885GLA 3760/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | ALDH1A1 1153/4885KDM4E 3122/4885GLA 3103/4885 |
| US-20150368287-A1 | NUCLEOSIDE AND NUCLEOTIDE HAVING NITROGEN-CONTAINING HETEROCYCLE STRUCTURE | NSUN2, NT5C3B, PNP | ALDH1A1 4655/4885KDM4E 3470/4885GLA 2762/4885 |
| US-20160331770-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | ALDH1A1 3576/4885KDM4E 2699/4885GLA 3760/4885 |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | ALDH1A1 2567/4885KDM4E 3498/4885GLA 3874/4885 |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | ALDH1A1 3576/4885KDM4E 2699/4885GLA 3760/4885 |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | ALDH1A1 2125/4885KDM4E 3768/4885GLA 2335/4885 |
| US-20150337002-A1 | NUCLEOSIDE AND NUCLEOTIDE HAVING SULFONAMIDE STRUCTURE | NSUN2, NR2E3, NR0B2 | ALDH1A1 4270/4885KDM4E 3879/4885GLA 3474/4885 |
| US-20130252920-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG | TYMP, POLN, POLRMT | ALDH1A1 1869/4885KDM4E 4682/4885GLA 2228/4885 |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | ALDH1A1 2755/4885KDM4E 4023/4885GLA 3411/4885 |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | ALDH1A1 2053/4885KDM4E 3467/4885GLA 2143/4885 |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | ALDH1A1 3169/4885KDM4E 3087/4885GLA 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.